Research programme: vascular diseases therapeutic antibodies - Wincal Biopharm
Latest Information Update: 28 Jul 2024
At a glance
- Originator Wincal Biopharm
- Class Antibodies; Vascular disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Pulmonary oedema; Vascular disorders
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for research development in Pulmonary-oedema in USA (Parenteral)
- 28 Jul 2024 No recent reports of development identified for research development in Vascular-disorders in USA (Parenteral)
- 03 Jun 2020 Early research in Pulmonary oedema in USA (Parenteral) (Wincal Biopharm website, June 2020)